Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and RCHOP in B Cell Non-Hodgkin's Lymphoma
NCT03147885Phase 2Active, not recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2017
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in B-cell non-Hodgkin lymphoma, sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Maximum Tolerated Dose of selinexor in combination with RCHOP at 21 days and Progression-Free Survival at 2 years. Started Jun 2017; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03147885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147885.